Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | NICE approves acalabrutinib for CLL in the UK

Toby Eyre, MD, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), Oxford University Hospitals NHS Foundation Trust, Oxford, UK, talks on the NICE approval of the Bruton’s tyrosine kinase inhibitor acalabrutinib for patients with chronic lymphocytic leukemia (CLL) in the UK, commenting on implications for clinical practice. Dr Eyre reports that the biggest impact of the approval will be in the front-line setting. Dr Eyre also highlights the approval of venetoclax in combination with obinutuzumab for patients with CLL.